Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

716
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
716

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The EPR effect in human tumors: a critical re-evaluation of a nanomedicine dogma and a call for new targeting paradigms.

Nanomedicine (London, England)·2026
Same author

Neuroprotection Through Nature: The Role of Bioactive Phytocompounds in Alzheimer's and Parkinson's Disease.

Current neurovascular research·2026
Same author

Nutritional Composition, Therapeutic Benefits, and Functional Food Potential of <i>Coleus amboinicus</i>: A Comprehensive Review.

Food science & nutrition·2026
Same author

Interplay of Genetic and Biomarker Signatures in Oxidative Stress and Inflammation: Advancing Parkinson's Disease Research Through Emerging Omics Technologies.

Current neurovascular research·2026
Same author

Targeting α-Synuclein Aggregation in Parkinson's Disease: A Narrative Review of Current Gene Therapy Strategies.

Current neuropharmacology·2026
Same author

Innovative Drug Delivery Strategies for Enhanced Treatment of Antimicrobial Resistance.

Current drug delivery·2026

相关实验视频

Updated: Sep 9, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K

心肌纤维化治疗目标:现有和新兴方法的全面审查

Ankita Wal1, Anurag Rawat2, Rakesh Verma3

  • 1Department of Pharmacy, PSIT-Pranveer Singh Institute of Technology, NH19 Kanpur Agra highway Bhauti Kanpur, Kanpur, India.

Cardiovascular & hematological disorders drug targets
|September 5, 2025
PubMed
概括

心肌纤维化对心力衰竭有很大影响, 目前的治疗方法不足. 针对不同分子机制的多面性治疗方法对于改善患者的结果至关重要.

关键词:
它们是RAAS抑制剂.SGLT2 抑制剂一种TGF-β抑制剂基质金属蛋白酶心肌纤维化

更多相关视频

Isolation and Characterization of Adult Cardiac Fibroblasts and Myofibroblasts
10:45

Isolation and Characterization of Adult Cardiac Fibroblasts and Myofibroblasts

Published on: March 12, 2020

16.2K
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.4K

相关实验视频

Last Updated: Sep 9, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K
Isolation and Characterization of Adult Cardiac Fibroblasts and Myofibroblasts
10:45

Isolation and Characterization of Adult Cardiac Fibroblasts and Myofibroblasts

Published on: March 12, 2020

16.2K
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.4K

科学领域:

  • 心血管医学
  • 分子生物学
  • 药理学

背景情况:

  • 心血管疾病是全球死亡的主要原因.
  • 心肌纤维化是心脏功能障碍和心力衰竭的关键因素.
  • 年轻人中心血管疾病死亡率的上升需要进行先进的研究.

研究的目的:

  • 审查心肌纤维化背后的分子机制.
  • 探索心肌纤维化的当前和新兴治疗策略.
  • 综合治疗心脏纤维化及其并发症的数据.

主要方法:

  • 在PubMed,Scopus,Elsevier和ClinicalTrials.gov的综合文献评论中.
  • 包括对心肌纤维化机制和治疗方法进行同行评审的英语研究.
  • 临床前和临床研究数据的定性综合.

主要成果:

  • 心肌纤维化源于诸如缺血和高脂血症之类的病态状况,
  • 传统的治疗方法 (RAAS抑制剂,β抑制剂) 可以缓解症状,但不能阻止纤维化的进展.
  • 涉及多个分子途径, 提供新的治疗目标.

结论:

  • 单一治疗不足以解决心肌纤维化的复杂病理生理问题.
  • 新兴疗法包括抗TGF-β药物,SGLT2抑制剂,MMP抑制剂和再生方法 (干细胞,基因疗法).
  • 针对各种分子机制的多面治疗策略对于改善心力衰竭的临床结果至关重要.